First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors - ScienceDirect

$ 18.50

4.7
(69)
In stock
Description

First-in-human study of the safety, pharmacokinetics, and

Lipids and cancer: Emerging roles in pathogenesis, diagnosis and

Pharmacokinetics and pharmacodynamics of SCT800, a new recombinant

Discovery of a mammalian FASN inhibitor against xenografts of non

Lost in FASN translation: from pre-clinical testing to first-in

Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP

Acetyl-CoA metabolism as a therapeutic target for cancer

Acetyl-CoA metabolism as a therapeutic target for cancer

FASN inhibitor TVB-3166 prevents S-acylation of the spike protein

Targeting fatty acid uptake and metabolism in cancer cells: A

Emerging roles of fatty acid metabolism in cancer and their

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640